Abstract
Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. Temozolomide frequently produces profound lymphopenia. We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature. Narrow monitoring with cytomegalovirus antigenemia assay should be considered for recommendation.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aged
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Central Nervous System Neoplasms / complications
-
Central Nervous System Neoplasms / drug therapy
-
Cytomegalovirus Infections / complications*
-
Cytomegalovirus Infections / epidemiology
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Female
-
Glioblastoma / complications
-
Glioblastoma / drug therapy
-
Humans
-
Lymphoma, B-Cell / complications
-
Lymphoma, B-Cell / drug therapy
-
Male
-
Middle Aged
-
Opportunistic Infections / complications
-
Temozolomide
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide